Differential Drug Resistance Acquisition in HIV-1 of Subtypes B and C
Author Information
Author(s): Soares Esmeralda A.J.M., Santos André F.A., Sousa Thatiana M., Sprinz Eduardo, Martinez Ana M.B., Silveira Jussara, Tanuri Amilcar, Soares Marcelo A.
Primary Institution: Universidade Federal do Rio de Janeiro
Hypothesis
Do HIV-1 subtypes B and C differ in the rate of accumulation of drug resistance mutations under antiretroviral therapy?
Conclusion
Subtype C accumulates drug resistance mutations at a lower rate than subtype B, which is important for antiretroviral therapy strategies in developing countries.
Supporting Evidence
- Subtype B showed a higher rate of drug resistance mutations compared to subtype C.
- Significant differences in drug resistance mutations were observed after 4 years of ARV exposure.
- Patients with subtype C had a lower proportion of resistant strains than those with subtype B.
Takeaway
This study found that HIV-1 subtype C gets fewer mutations that make it resistant to drugs compared to subtype B, which is important for treating HIV in places where subtype C is common.
Methodology
Viral RNA was extracted from 160 HIV-1 positive patients, and the protease and reverse transcriptase genes were sequenced and analyzed for ARV mutations.
Potential Biases
Potential biases may arise from the selection of patients and their treatment histories.
Limitations
The study was limited to patients in southern Brazil and may not be generalizable to other regions.
Participant Demographics
Patients were HIV-1 positive adults with a mix of subtypes B and C, with varying treatment histories.
Statistical Information
P-Value
p=0.0012 for NRTI, p=0.0288 for PI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website